Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04261712 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance)
A Phase 2 study of Acromegaly, sponsored by Crinetics Pharmaceuticals.
- Active
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
- 20
- Study locations
NCT04261712: Active Phase 2 study of Acromegaly, sponsored by Crinetics Pharmaceuticals.
NCT04261712 is a Phase 2 study of Acromegaly that is active but no longer recruiting, run by Crinetics Pharmaceuticals. The registered enrollment target is 43 participants, below the 98-participant average among 13 other Acromegaly trials with a reported enrollment target (56% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04261712, a Phase 2 study of Acromegaly, is active but no longer recruiting, sponsored by Crinetics Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
- 20
- Study locations
Study Summary
A phase 2, open label, long-term extension study designed to evaluate the safety and efficacy of paltusotine (formerly CRN00808; an oral selective nonpeptide somatostatin receptor type 2 biased agonist) in subjects with acromegaly.
Conditions Studied
Interventions
- DRUG Paltusotine
Study Locations (20)
Other
- Crinetics Study Site - Rio de Janeiro
- Crinetics Study Site - Rio de Janeiro
- Crinetics Study Site - São Paulo
- Crinetics Study Site - München
- Crinetics Study Site - Athens
- Crinetics Study Site 1 - Athens
- Crinetics Study Site 2 - Athens
- Crinetics Study Site - Thessaloniki
- Crinetics Study Site - Budapest
- Crinetics Study Site - Budapest
- Crinetics Study Site - Pécs
- Crinetics Study Site - Belgrade
Pennsylvania
- Crinetics Study Site - Pittsburgh
- Crinetics Study Site - Pittsburgh
California
- Crinetics Study Site - Los Angeles
Illinois
- Crinetics Study Site - Chicago
Massachusetts
- Crinetics Study Site - Boston
Ohio
- Crinetics Study Site - Columbus
Texas
- Crinetics Study Site - Dallas
Paraná
- Crinetics Study Site - Curitiba
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2020-01-29 |
| Est. Completion | 2028-03 |
| Phase | Phase 2 |
What the registry record for NCT04261712 still lists
NCT04261712 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 98-participant average among 13 other Acromegaly trials with a reported enrollment target (56% lower).
The record links to 1 condition, with Acromegaly appearing as the primary indexed condition, and to 1 intervention - of which Paltusotine is the first listed.
NCT04261712 names 20 study sites across 8 states, led by Other, Pennsylvania, California.
Frequently Asked Questions
What is clinical trial NCT04261712 about?
NCT04261712 is a clinical study titled "A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance)". A phase 2, open label, long-term extension study designed to evaluate the safety and efficacy of paltusotine (formerly CRN00808; an oral selective nonpeptide somatostatin receptor type 2 biased agonist) in subjects with acromegaly.
What is the current status of trial NCT04261712?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2020-01-29. Estimated completion is 2028-03.
What conditions does trial NCT04261712 study?
This clinical trial studies the following conditions: Acromegaly.
What interventions are being tested in trial NCT04261712?
The interventions under investigation include: Paltusotine (DRUG).
Who is sponsoring clinical trial NCT04261712?
This trial is sponsored by Crinetics Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04261712 being conducted?
This trial has 20 study locations across California, Illinois, Massachusetts, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acromegaly
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04261712's enrollment target sits among peer trials
43 11th of 13 higher than 3 of 13 other Acromegaly trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acromegaly trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly
RECRUITING · Phase 2
-
Sandostatin LAR Depot vs. Surgery for Treating Acromegaly
COMPLETED · Phase 2
-
A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs
RECRUITING · Phase 3
-
Diet in the Management of Acromegaly
RECRUITING · NA
-
Study of MAR002 in Healthy Men
RECRUITING · Phase 1
-
Peri-operative Dynamics of the Growth Hormone Axis in Subjects With Acromegaly
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI